The effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor (SNRI) on the obsessive compulsive disorder (OCD) model, marble burying behavior, were investigated in mice. Milnacipran above the dosage of 10 mg/kg inhibited marble burying behavior significantly in mice as similar to fluvoxamine. Milnacipran inhibiting marble burying behavior did not affect locomotor activity. These results suggest that milnacipran can inhibit marble burying behavior and that milacipran may be useful for OCD therapy.
Serotonin (5-HT) has been suggested to have significant roles in several psychiatric disorders, including depression and anxiety. 1) Obsessive compulsive disorder (OCD) is classified as an anxiety disorder characterized by obsession or compulsion.
2) The burying of harmless objects like marbles by mice may reflect the formation of compulsive behavior. Marble burying behavior in mice is recognized as an animal model for OCD.
3) It has been reported that marble burying behavior is inhibited by anxiolytics such as diazepam.
3) This behavior is also attenuated by treatment with selective serotonin reuptake inhibitors (SSRIs). 3, 4) We previously reported that several SSRIs, fluvoxamine, sertraline and paroxetine inhibit marble burying behavior in mice.
5) SSRIs, including fluvoxamine or citalopram, are effective for OCD in humans and are used as standard drugs for the treatment for OCD. 1, 2) These findings suggest that serotonergic activity may be closely related to OCD and marble burying behavior in mice may also be derived from defect of 5-HT.
Milnacipran is an antidepressant, which selectively inhibits the reuptake of both 5-HT and noradrenaline, that is, milnacipran is a serotonin and noradrenaline reuptake inhibitor (SNRI). 6, 7) Tricyclics including imipramine also inhibits the reuptake of both noradrenaline and 5-HT, although they have anti-cholinergic activity, which leading to several side effects. 6, 7) In contrast, milnacipran improves depression without anti-cholinergic activity. 6, 7) Therefore, there is increasing interest in milnacipran for the treatment of depression. However, it has not yet been clarified whether milnacipran is effective in OCD. Therefore, in the present study, we investigated the effects of milnacipran on the OCD model, marble burying behavior in mice, and compared with the effects of a SSRI, fluvoxamine.
MATERIALS AND METHODS

Animals
Male and ICR mice weighing 25-30 g were used in experiments (Japan SLC Inc., Shizuoka, Japan). Mice were with free access to food and water, and were maintained on a 12 h dark/light cycle in a room with controlled temperature (23Ϯ1°C) and humidity (55Ϯ5%). This study was conducted according to guidelines approved by the Experimental Animal Ethical Committee of Kobe Pharmaceutical University.
Drug Milnacipran HCl and fluvoxamine maleate were obtained from Tocris (U.K.) and Sigma (U.S.A.), respectively. Milnacipran and fluvoxamine were dissolved in saline and injected i.p. and marble burying behavior was determined 30 min after treatment with milnacipran or fluvoxamine.
Marble Burying Behavior Marble burying test was performed according to the modified method of Njung'e and Handley.
3) Marbles buried by mice for 30 min were counted. For the marble-burying test, an open cubic transparent plastic box (22.5 cmϫ33.8 cmϫ14.0 cm) was used, and 20 clean glass marbles (15 mm diameter) were evenly spaced (5 cm apart) on sawdust (5 cm deep) as previously described. 5) Mice were placed into the cubic box for 30 min, and experimenters counted the number of marbles covered with sawdust. The spontaneous activity of animals during the testing period was also counted by an activity sensor (NS-AS01, Neuroscience Inc., Tokyo, Japan).
Statistical Analysis Data were analyzed by the one way analysis of variance (ANOVA) followed by Dunnett's test. Figure 1 shows the effects of fluvoxamine and milnacipran on marble behavior in mice. Fluvoxamine reduced marble burying behavior dose-dependently.
RESULTS
Effects of Fluvoxamine and Milnacipran on Marble Burying Behavior
Milnacipran inhibited marble burying behavior above the dosage of 10 mg/kg and in mice treated with 20 mg/kg, the number of marbles buried reduced by 30% of the control group.
Effects of Fluvoxamine and Milnacipran on Locomotor Activity Locomotor activity for 30 min after the injection of fluvoxamine and milnacipran did not change compared to the saline-treated group (Fig. 2) . 
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classified as SNRIs. Milnacipran is clinically used for the treatment of depression. 7, 8) SNRIs selectively inhibit the reuptake of 5-HT and noradrenaline, avoiding affinity with several neurotransmitter receptor binding sites. 7, 8) They have very low affinity with muscarinic, beta, H 1 receptors. 7, 8) Therefore, in the therapy for depression, SNRIs have the benefits of minimal side effects based on low affinity with these receptors, while tricyclic antidepressants such as imipramine have several side effects derived from their blockade of muscarinic receptors.
It has been reported that in mice and rats, a SNRI, milnacipran has antidepressant effects, since it reduces immobility time in the forced swimming test, which is used for the evaluation of antidepressants. 6, 9) SSRIs, which selectively inhibit 5-HT reuptake, are widely used as antidepressants. SSRIs are also effective in other psychiatric disorders including panic disorder and anxiety. 1) SSRIs are useful for an anxiety disorder, OCD. 1, 2) It has been identified that SSRIs are the drugs mostly used for OCD therapy. 1, 2) Marble burying behavior in mice is an OCD model and SSRIs can strongly inhibit marble burying behavior. 3, 4) This evidence suggests that the serotonergic system is closely related to marble burying behavior or OCD. As milnacipran strongly inhibits 5-HT reuptake, it is assumed that it may reduce marble burying behavior.
In the present study, we confirmed that a typical SSRI, fluvoxamine, dose-dependently inhibited marble burying behavior, the results of which are consistent with the results in previous reports. 4) We also previously reported that fluvoxamine by oral administration inhibits marble burying behavior in mice, 5) further supporting the present results. As shown in results, milnacipran can inhibit marble burying behavior in mice in similar doses as fluvoxamine. Neither fluvoxamine nor milnacipran at doses used in this study affected locomotor activity. Therefore, inhibition of marble burying behavior of fluvoxamine and milnacipran is not related to locomotor activity. Furthermore, it was reported that milnacipran has anti-immobility effects in the forced swimming test at a doses of 30-60 mg/kg p.o., which is in the same range as that inhibiting marble burying behavior. 9) These results indicate that milnacipran can inhibit marble burying behavior and that milnacipran may be effective for OCD as well as depression.
Marble burying behavior was inhibited by SSRIs or tricyclic antidepressant clomipramine with high affinity of 5-HT transporter. [3] [4] [5] However, this behavior was not altered by noradrenaline reuptake inhibitors.
3) Although milnacipran can inhibit the reuptake of both 5-HT and noradrenaline, 6) inhibitory effects of milnacipran on marble burying behavior are probably derived from its action on the serotonergic system. It was reported that inhibitory effects of fluvoxamine on marble burying behavior may be mediated by the 5-HT 1A receptor, since it was inhibited by the 5-HT 1A receptor antagonist NAN-190. 4) Although the mechanism of milnacipran is uncertain, inhibitory effects of milnacipran may also be associated with the 5-HT 1A receptor.
Our results suggest that a SNRI, milnacipran, diminished the OCD model, marble burying behavior similar to a SSRI, fluvoxamine. Although SSRIs are the first drugs for therapy of OCD, about 40% patients do not respond to SSRIs. 10) Recently the SNRI venlafaxine is effective in the SSRI-resistant OCD patients. 10 ) Therefrore, it is suggested that SNRIs may be beneficial for treatment of OCD unresponding to SSRIs. Milnacipran is applied clinically as an antidepressant. 6, 7) Our results demonstrate that milnacipran may be useful in OCD in addition to depression. Ministry of Education, Culture, Sports, Science and Technology of Japan.
